BerandaMLLCF • OTCMKTS
add
Molecular Partners AG
Tutup sebelumnya
$6,52
Rentang tahun
$3,40 - $10,14
Kapitalisasi pasar
245,02 jt USD
Volume Rata-Rata
53,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
SWX
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CHF) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 2,74 jt | -10,23% |
Biaya operasional | 4,49 jt | -17,47% |
Laba bersih | -11,32 jt | 23,37% |
Margin laba bersih | -413,62 | 14,63% |
Penghasilan per saham | — | — |
EBITDA | -15,25 jt | -5,35% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 174,13 jt | -25,06% |
Total aset | 185,60 jt | -24,10% |
Total liabilitas | 17,06 jt | -23,74% |
Total ekuitas | 168,54 jt | — |
Saham yang beredar | 32,87 jt | — |
Harga terhadap reservasi | 1,27 | — |
Tingkat pengembalian aset | -20,65% | — |
Pengembalian modal | -22,53% | — |
Arus Kas
Perubahan bersih tunai
| (CHF) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -11,32 jt | 23,37% |
Kas dari operasi | -17,05 jt | -3,05% |
Tunai dari investasi | 17,61 jt | 422,58% |
Tunai dari pembiayaan | -300,00 rb | -1,01% |
Perubahan bersih tunai | 1,04 jt | 107,39% |
Arus kas bebas | -11,21 jt | -30,15% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
168
